Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 320-326

  Koudriavtseva, T ^a   Sbardella, E ^a   Trento, E ^b   Bordignon, V ^b   D'Agosto, G ^b   Cordiali Fei, P ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Lymphocyte subsets; Multiple sclerosis; Natalizumab

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CD4 CD8 RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

LYMPHOCYTE SUBSETS; MULTIPLE SCLEROSIS; NATALIZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; RETROSPECTIVE STUDIES;

EID: 84899082996     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12261     Document Type: Article

References (19)

1. Miller DH, Khan OA, Sheremata WA etal. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
2. Wipfler P, Oppermann K, Pilz G etal. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler 2011; 17:16-23.
3. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71:1350-1354.
4. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 2010; 63:311-317.
5. Skarica M, Eckstein C, Whartenby KA, Calabresi PA. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 2011; 235:70-76.
6. Planas R, Jelčić I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012; 42:790-798.
7. Zanotti C, Chiarini M, Serana F etal. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clin Immunol 2012; 145:19-26.
8. Ryan DH, Nuccie BL, Abboud CN, Winslow JM. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 1991; 88:995-1004.
9. Niino M, Bodner C, Simard ML etal. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748-754.
10. Mellergård J, Edström M, Jenmalm MC, Dahle C, Vrethem M, Ernerudh J. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients. PLOS One 2013; 8:e81685. doi:10.1371/journal.pone.0081685.
11. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111:3439-3441.
12. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD341 hematopoietic progenitor cells in humans. Blood 2008; 111:3893-3895.
13. Jing D, Oelschlaegel U, Ordemann R etal. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45:1489-1496.
14. Frisullo G, Iorio R, Plantone D etal. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 2011; 17:556-566.
15. Kivisäkk P, Healy BC, Viglietta V etal. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72:1922-1930.
16. Polman CH, Reingold SC, Edan G etal. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58:840-846.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
18. Foley J. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis. Am J Manag Care 2010; 16 (6 Suppl.):S178-183.
19. Sottini A, Capra R, Zanotti C etal. Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient. PLOS One 2012; 7:34493.